Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade

Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses

(2021) Jennifer A. Lo et al.   Science Translational Medicine

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy

(2021) Ana Marcu et al.   Journal for ImmunoTherapy of Cancer

Integrated analysis of multimodal single-cell data

(2021) Yuhan Hao et al.   CELL

Comprehensive T cell repertoire characterization of non-small cell lung cancer

(2020) Alexandre Reuben et al.   Nature Communications

Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening

(2020) Huang Huang et al.   NATURE BIOTECHNOLOGY

Moving towards personalized treatments of immune-related adverse events

(2020) Khashayar Esfahani et al.   Nature Reviews Clinical Oncology

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

(2019) Fiamma Berner et al.   JAMA Oncology

Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors

(2019) Fausto Petrelli et al.   JOURNAL OF IMMUNOTHERAPY

Vitiligo under anti-PD1 therapy is associated with increased survival in melanoma patients

(2019) Charlée Nardin et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Fast, sensitive and accurate integration of single-cell data with Harmony

(2019) Ilya Korsunsky et al.   NATURE METHODS

Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors

(2019) Sophia C Weinmann et al.   RHEUMATOLOGY

Induction of Neoantigen-specific Cytotoxic T Cells and Construction of T-cell Receptor-engineered T cells for Ovarian Cancer

(2018) Tatsuo Matsuda et al.   CLINICAL CANCER RESEARCH

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells

(2018) Jolien J. Luimstra et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy

(2018) Tatjana Bilich et al.   BLOOD

Tools to define the melanoma-associated immunopeptidome

(2017) Eva Bräunlein et al.   IMMUNOLOGY

NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

(2017) Vanessa Jurtz et al.   JOURNAL OF IMMUNOLOGY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

The human protein atlas: A spatial map of the human proteome

(2017) Peter J. Thul et al.   PROTEIN SCIENCE

Neutrophils dominate the immune cell composition in non-small cell lung cancer

(2017) Julia Kargl et al.   Nature Communications

SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity

(2017) Jungsun Park et al.   Cancer Immunology Research

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

(2016) Mizuki Nishino et al.   JAMA Oncology

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melanocytes in the Skin – Comparative Whole Transcriptome Analysis of Main Skin Cell Types

(2014) Paula Reemann et al.   PLoS One

HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)

(2014) Daniel J. Kowalewski et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

Full screening and accurate subtyping of HLA-A*02 alleles through group-specific amplification and mono-allelic sequencing

(2013) Shengli Song et al.   Cellular & Molecular Immunology

The Effect of Proteasome Inhibition on the Generation of the Human Leukocyte Antigen (HLA) Peptidome

(2013) Elena Milner et al.   MOLECULAR & CELLULAR PROTEOMICS

Napsin A, a New Marker for Lung Adenocarcinoma, Is Complementary and More Sensitive and Specific Than Thyroid Transcription Factor 1 in the Differential Diagnosis of Primary Pulmonary Carcinoma: Evaluation of 1674 Cases by Tissue Microarray

(2012) Bradley M. Turner et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

Quantitative signal detection using spontaneous ADR reporting

(2009) A. Bate et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY